Press release

DSM strengthens end-to-end gut health solutions in North American market with FDA NDI status strains

Parsippany (US), 17 Feb 2022

Royal DSM, a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living, today announced that it has bolstered its capabilities as an end-to-end partner for North American customers in the gut health space. This follows New Dietary Ingredient (NDI) status of its Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri 12246-CU probiotic strains, issued by the Food and Drug Administration (FDA) without objection. By bringing its consumer insights and scientific and applications know-how to the category, the move will enable dietary supplement brands in the region to explore new innovations, and ultimately expand their portfolios to cater for the booming gut health trend. 

As microbiome science continues to evolve, the world’s understanding of the link between good gut health and overall wellbeing is taking shape. The DSM Consumer Health Concerns Study 2021 – which surveyed almost 19,000 consumers across 24 countries – revealed that 61% of consumers worldwide are now concerned about their gut health and 67% of those take action to support it. In order to continue supporting cutting-edge innovation in the field, DSM’s leading probiotic strains are now available to customers in the US region as purpose-led market-ready solutions driven by what connects with consumers. 

The strains – Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri 12246-CU demonstrate multiple clinically-proven gut-related benefits when combined, including improved digestive comfort and reduced diarrhea. The accessibility of these strains in the US follows the recent ‘No Objection of NDI submission’ by the FDA. The strains are already commercially available in Europe, Asia and the Middle East.

“Our growing global presence in the gut health market signifies our continued investment in this trending category, where growth is driven by changing consumer mindsets,” says Jill Porter, Global Director Gut Health, Dietary Supplements, DSM. “Customers can trust that DSM will help them navigate the developing science and awareness around holistic gut health – enabling them to bring targeted health solutions to market faster. We’ve already developed a number of inspiring product concepts with strong consumer appeal, to demonstrate how customers can leverage our DSM strains as part of our industry-leading portfolio to develop 100% finished, health benefit-driven solutions packed with purpose.”

“The NDI status of our two flagship strains strengthens confidence in our science-based ingredients and creates a multitude of opportunities for our US-based customers to remain at the forefront of the market,” says Penny Antonopoulos, Director Dietary Supplements, Human Nutrition & Care, North America, DSM. “Both strains were identified as among the best performing probiotic varieties – out of a total of 47 – by a large and comprehensive screening program. Both strains, for example, demonstrated excellent pH tolerance and adhesion properties to enable passage through the gastrointestinal tract and strong antimicrobial activity against pathogenic bacteria.1,2 Because of this, the strains were specifically chosen to support customers looking to innovate in the gut health space across a number of applications.”

Connect with a DSM expert today to learn more about how you can leverage our gut health capabilities to innovate across the dietary supplement and early life nutrition markets

DSM – Bright Science. Brighter Living.™

Royal DSM is a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM’s purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world’s biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at


Forward-looking statements
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.


1 Rosenfeldt et al. Faecal recovery, mucosal adhesion, gastrointestinal effects and tolerance of mixed cultures of potential probiotic Lactobacilli. Microbial Ecology in Health and Disease, 2003.

2 Jacobsen et al. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Applied and Environmental Microbiology. 1999.

For more information

Kristen Walker

DSM Human Nutrition & Health
Regional Head of Marketing Communications

Eleanor Tarling

Barrett Dixon Bell
+44 161 925 4700